Morepen LaboratoriesQ1 FY22

Morepen Laboratories Q1 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹94.66P/E: 27.5Market Cap: ₹5.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • The company achieved a 50% revenue growth in Q1 FY22, a phenomenal increase from previous quarters.
  • Dr. Morepen portfolio is expected to grow to around Rs.1,000 crores in the next two years, indicating strong growth in OTC and medical devices.
  • Diagnostics division sales grew 189% this quarter, with an increasing share of the company’s revenue; the division is expected to remain a key growth driver.
  • API business growth is steady at 17% with plans to focus on new molecules and products linked to a $40 billion market with expiring patents.
  • Medical Devices segment expanding capacity and adding new products, projected to keep growing along with Finished Dosage business recovery (30% growth).
  • COVID-driven demand for diagnostic devices may normalize but heightened health awareness is expected to sustain higher usage and sales long-term.
  • Overall company poised for continued robust growth fueled by expansion in diagnostics, formulations, and new product launches.

See what Morepen Laboratories management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • No immediate plans for new fundraising through equity or debt as the company currently has sufficient cash flows.
  • Past preferential allotment was postponed to seek higher prices; discussions with investors are ongoing but no final decisions made.
  • The company is open to taking term loans for buildings or other needs if required but has not yet signed any agreements.
  • CAPEX for the current year (around Rs.35-40 crores) and investments in Medical Devices (around Rs.20 crores) will be funded through internal accruals.
  • Working capital requirements are increasing, and the company may consider local arrangements for working capital financing if needed.
  • Management is keen on wealth creation for all shareholders and cautious about undervaluation in any fundraising.

See what Morepen Laboratories management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Total CAPEX requirement is Rs.178 crores over three years; Rs.35-40 crores expected to be spent in the current year.
  • API segment investment of Rs.35-40 crores planned from internal accruals.
  • Medical Devices segment to receive around Rs.20 crores investment, also from internal accruals.
  • Potential backward integration for intermediate chemicals currently imported from China.
  • Additional investment may be needed for new API plant building and machinery; higher CAPEX expected next financial year.
  • Open to term loans if required for buildings or working capital but currently relying on internal accruals.
  • No major investments planned yet for Sputnik vaccine bulk production; only working capital might be needed.
  • Strategic focus on biosimilars and new biological products with expansions aligning to these areas.

Track Morepen Laboratories — get its next earnings analysis in your feed

How does Morepen Laboratories rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisMorepen Laboratories
Rev 2Mar 3

How does Morepen Laboratories rank in Pharmaceuticals & Biotechnology?

Compare Morepen Laboratories against every Pharmaceuticals & Biotechnology company (Q1 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →